Jupiter Neurosciences (JUNS) Net Cash Flow (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Net Cash Flow of -$2.4 million for Q4 2025, down 162.82% year-over-year from $3.8 million in Q4 2024, and down 105.12% quarter-over-quarter from -$1.2 million in Q3 2025.
Jupiter Neurosciences (JUNS) Net Cash Flow (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Net Cash Flow for 3 consecutive years, with -$2.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 162.82% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$5.4 million (down 244.71% YoY), while the FY2025 annual figure was $19832.0, down 99.47% from the prior year.
- Net Cash Flow eased to -$2.4 million in Q4 2025 per JUNS's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $3.8 million in Q4 2024 and bottomed at -$2.4 million in Q4 2025.
- Historically, Net Cash Flow has averaged -$189315.7 across 3 years, with a median of -$31137.0 in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow surged 12205.4% — and 2025, when it plunged 12767.82%.
- Jupiter Neurosciences' Net Cash Flow stood at -$31137.0 in 2023, then soared by 12205.4% to $3.8 million in 2024, then slumped by 162.82% to -$2.4 million in 2025.
- Business Quant data shows JUNS's Net Cash Flow at -$2.4 million in Q4 2025, -$1.2 million in Q3 2025, and -$828222.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.37 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -828,222.00 |
| Jun 30, 2025 | -828,222.00 |
| Mar 31, 2025 | -1.06 Mn |
| Mar 31, 2025 | -1.06 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | -14,598.00 |
| Sep 30, 2024 | -14,598.00 |
| Jun 30, 2024 | 6,538.00 |
| Jun 30, 2024 | 6,538.00 |
| Mar 31, 2024 | -20,165.00 |
| Mar 31, 2024 | -20,165.00 |
| Dec 31, 2023 | -31,137.00 |
| Dec 31, 2023 | -31,137.00 |